- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02760472
A Fatty Acids Study in Preventing Retinopathy of Prematurity (DonnaMega)
A Randomised Intervention Single Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity
Most fatty acids, important for development and especially the Omega-3 fatty acids for the brain development are transferred in the third trimester with means that in the premature infant this transport via the placenta is interrupted and the infant is dependent on the concentrations in breast milk which vary depending on the mother's diet and her stores. It has even been suggested that low Omega-3 would be a cause of premature delivery. Many countries have much higher levels of Omega-3 fatty acids in breast milk than found in Sweden and breast milk substitutions are generally now supplemented with the Long Chained Poly Unsaturated Fatty Acids (LCPUFA). Therefore the supplementation to be given can not be seen to give any risks for the infant. On the contrary, several studies have shown that mother who eat equal to or less than twice fish a week during pregnancy give birth to infants with impaired development.
Low Omega-3 levels in premature infants between gestational ages of 23 and 40 weeks can be one reason for Retinopathy of Prematurity (ROP) development. Restoration of Omega-3, Dokosahexaenacid (DHA) and Eikosapentaenacid (EPA) to normal in utero levels may prevent ROP by allowing normal vessel growth and survival. An increase of Omega-3 levels bringing levels to within physiological range may prevent development of ROP.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a Randomised Intervention, Single-Center Study to Determine the Role of Fatty Acids in Serum and Breast Milk in preventing Retinopathy of Prematurity.
Subjects who meet all inclusion and none of the exclusion criteria will be enrolled into the study. Upon entry into the study, subjects will be randomized and given a unique subject number.
A randomised intervention study of 45+45 infants without major malformations born with a gestational age less than 28 weeks + 0 days will be performed.
Randomization of the patients to either:
Conventional fatty acid supplementation regime with Clinoleic (with Vitalipid infant and Soluvit supplementation) to the preterm infant
Or
- SMOFlipid, (soybean oil, medium chain triglycerides, olive oil and fish oil),(with Vitalipid infant and Soluvit supplementation), where the quotient of Omega 6:3 is 2.5:1 in order to mimic the physiologic relation of fatty acids in cord blood from birth, to the preterm infant.
Thus there is one group of infants (n=45) that will receive Omega-3 in the fatty acid supplementation.
The time on parenteral nutrition and the amount of fatty acids given will be according to clinical routines.
The randomization of the patients will be performed by the controller of the study. Randomization will be in blocks with 10 children in each block.
Data collection
After the investigators have received informed consent from the parents/guardians, blood samples 0.2 ml from the child will be taken according to present clinical practice at if possible from cord (2ml) and at days 0, 7, 14, 28 and in postmenstrual weeks 32, 36 and 40. Blood samples from the mothers for Fatty Acids analyses will be taken after birth, day 7 and at gestational weeks 36 and 40. At the same time (except from day 1), breast milk samples are taken. Length in cm, weight in gram and head circumference in cm are measured weekly.
Screening for ROP will be performed, at least once a week, according to clinical routines using a specific protocol.
The investigators intend to analyze the content of phospholipids which can be done on small amounts of blood, is relatively insensitive to short term fluctuations in intake and mirror the composition of many membranes in the body. The analyses will be made using gas-liquid chromatography. The method has a coefficient of variability of 1-3% for the Fatty Acids concerned.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent from parents/guardians;
- Subject must be below 28 weeks of gestation
Exclusion Criteria:
- Detectable clinical gross malformation;
- Known or suspected chromosomal abnormality, genetic disorder, or syn-drome, according to the investigator's opinion;
- Clinically significant neuropathy, nephropathy, retinopathy, or other micro- or macrovascular disease requiring treatment, according to the investigator's opinion;
- Any other condition or therapy that, in the investigator's opinion, may pose a risk to the subject or interfere with the subject's ability to be compliant with this protocol or interfere with interpretation of results.
- Bleeding disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Clinoleic
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
|
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
|
Experimental: SMOFlipid
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
|
Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Retinopathy of Prematurity
Time Frame: When the retina is fully vascularised,i.e. at approximately 40 postmenstrual weeks.
|
We intend to analyze the content of Fatty Acids and correlate to Retinopathy of Prematurity development and interventional treatment.
Analyze of phospholipids can be done on small amounts of blood, is relatively insensitive to short term fluctuations in intake and mirror the composition of many membranes in the body.
The analyses will be made using gas-liquid chromatography.
The method has a coefficient of variability of 1-3% for the Fatty Acids concerned.
|
When the retina is fully vascularised,i.e. at approximately 40 postmenstrual weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain Growth
Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Cranial ultrasound will be performed according to clinical praxis.
MRI of the brain will be performed at 40 weeks postmenstrual age (PMA) and correlated to interventional treatment.
|
At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Length in cm
Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Length in cm given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.
|
At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Weight in gram
Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Weight in gram given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.
|
At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Head circumference in cm
Time Frame: At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Head circumference in cm given in absolute values and in standard deviation scores, at 40 weeks postmenstrual age (PMA) and at 2.5 and 6 years will be correlated to interventional treatment.
|
At 40 postmenstrual weeks and at 2.5 and 6 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carola Pfeiffer-Mosesson, RN, The Queen Silvia Children's Hospital
Publications and helpful links
General Publications
- Cakir B, Hellstrom W, Tomita Y, Fu Z, Liegl R, Winberg A, Hansen-Pupp I, Ley D, Hellstrom A, Lofqvist C, Smith LE. IGF1, serum glucose, and retinopathy of prematurity in extremely preterm infants. JCI Insight. 2020 Oct 2;5(19):e140363. doi: 10.1172/jci.insight.140363.
- Nilsson AK, Pedersen A, Malmodin D, Lund AM, Hellgren G, Lofqvist C, Pupp IH, Hellstrom A. Serum choline in extremely preterm infants declines with increasing parenteral nutrition. Eur J Nutr. 2021 Mar;60(2):1081-1089. doi: 10.1007/s00394-020-02312-2. Epub 2020 Jun 25.
- Lundgren P, Hellgren G, Pivodic A, Savman K, Smith LEH, Hellstrom A. Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity. Pediatr Res. 2019 Aug;86(2):276-282. doi: 10.1038/s41390-018-0186-6. Epub 2018 Sep 18.
- Lofqvist CA, Najm S, Hellgren G, Engstrom E, Savman K, Nilsson AK, Andersson MX, Hard AL, Smith LEH, Hellstrom A. Association of Retinopathy of Prematurity With Low Levels of Arachidonic Acid: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2018 Mar 1;136(3):271-277. doi: 10.1001/jamaophthalmol.2017.6658. Erratum In: JAMA Ophthalmol. 2018 Sep 1;136(9):1078.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Infant, Newborn, Diseases
- Pregnancy Complications
- Obstetric Labor Complications
- Obstetric Labor, Premature
- Infant, Premature, Diseases
- Retinal Diseases
- Premature Birth
- Retinopathy of Prematurity
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Fat Emulsions, Intravenous
- SMOFlipid
Other Study ID Numbers
- 2008-000046-31
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinopathy of Prematurity
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsTerminatedRetinopathy of Prematurity (ROP)United States
-
Novartis PharmaceuticalsCompletedRetinopathy of Prematurity (ROP)United States, Austria, Belgium, Croatia, Czechia, Denmark, Egypt, France, Germany, Greece, Hungary, India, Italy, Japan, Malaysia, Romania, Russian Federation, Saudi Arabia, Slovakia, Taiwan, Turkey, United Kingdom, Lithuania, Estonia
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, Poland, Sweden, United Kingdom
-
BayerRegeneron PharmaceuticalsCompletedAflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)Retinopathy of Prematurity (ROP)Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
-
University Hospital FreiburgCompletedRetinopathy of Prematurity (ROP)Germany
-
Zagazig UniversityCairo UniversityRecruitingRetinopathy of Prematurity Both EyesEgypt
-
ShireCompletedRetinopathy of Prematurity (ROP)United States, Italy, Netherlands, United Kingdom, Sweden, Poland
-
University Hospital FreiburgWithdrawn
-
BayerRegeneron PharmaceuticalsActive, not recruitingRetinopathy of Prematurity (ROP)Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Belgi...
-
Georgetown UniversityCompleted
Clinical Trials on Clinoleic
-
The First Affiliated Hospital with Nanjing Medical...Baxter Healthcare CorporationUnknownNutritional Supplement ToxicityChina
-
General University Hospital, PragueCharles University, Czech Republic; Ministry of Health, Czech RepublicCompletedParenteral NutritionCzechia
-
Klinikum LudwigshafenCompletedInflammatory Response | Hepatic FunctionGermany
-
Johane AllardCompletedCancer | Malnutrition | Surgery | Ileus | ObstructionCanada
-
Shanghai Jiao Tong University School of MedicineUnknownPreterm InfantsChina
-
Wei CaiUnknownPreterm InfantChina
-
Methodist Research Institute, IndianapolisTerminatedAcute Respiratory Distress SyndromeUnited States
-
Emory UniversityBaxter Healthcare CorporationCompletedInsulin Sensitivity | Diseases, MetabolicUnited States
-
Fernandes Tavora HospitalHospital Bandeirantes; Hospital Santa Luzia; Hospital Samaritano; Hospital da Polícia... and other collaboratorsCompletedParenteral NutritionGuatemala, Argentina, Brazil
-
Emory UniversityBaxter Healthcare CorporationCompletedParenteral NutritionUnited States